FR07C0046I2 - Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b - Google Patents

Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b

Info

Publication number
FR07C0046I2
FR07C0046I2 FR07C0046C FR07C0046C FR07C0046I2 FR 07C0046 I2 FR07C0046 I2 FR 07C0046I2 FR 07C0046 C FR07C0046 C FR 07C0046C FR 07C0046 C FR07C0046 C FR 07C0046C FR 07C0046 I2 FR07C0046 I2 FR 07C0046I2
Authority
FR
France
Prior art keywords
desoxy
nucleosides
hepatitis
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0046C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idenix Cayman Ltd
Original Assignee
Idenix Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0046(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idenix Cayman Ltd filed Critical Idenix Cayman Ltd
Publication of FR07C0046I1 publication Critical patent/FR07C0046I1/fr
Application granted granted Critical
Publication of FR07C0046I2 publication Critical patent/FR07C0046I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
FR07C0046C 1998-08-10 2007-09-21 Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b Active FR07C0046I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9611098P 1998-08-10 1998-08-10
US13135299P 1999-04-28 1999-04-28
PCT/US1999/018149 WO2000009531A2 (fr) 1998-08-10 1999-08-10 β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B

Publications (2)

Publication Number Publication Date
FR07C0046I1 FR07C0046I1 (fr) 2007-10-26
FR07C0046I2 true FR07C0046I2 (fr) 2008-05-09

Family

ID=26791121

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0046C Active FR07C0046I2 (fr) 1998-08-10 2007-09-21 Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b

Country Status (22)

Country Link
US (5) US6395716B1 (fr)
EP (2) EP1104436B1 (fr)
JP (2) JP4294870B2 (fr)
KR (4) KR100568035B1 (fr)
CN (3) CN1257912C (fr)
AT (1) ATE313550T1 (fr)
AU (1) AU5475799A (fr)
BR (1) BRPI9912896B8 (fr)
CA (1) CA2340156C (fr)
CY (2) CY2007017I2 (fr)
DE (2) DE122007000062I1 (fr)
DK (3) DK1431304T3 (fr)
ES (3) ES2579903T3 (fr)
FR (1) FR07C0046I2 (fr)
HK (3) HK1034083A1 (fr)
LU (1) LU91348I2 (fr)
MX (1) MXPA01001507A (fr)
NL (1) NL300286I2 (fr)
PT (2) PT1431304E (fr)
RU (1) RU2424016C2 (fr)
SG (1) SG132498A1 (fr)
WO (1) WO2000009531A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
WO2000009531A2 (fr) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1600452A3 (fr) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthèse de 2'-déoxy-L-nucléosides
MXPA02004779A (es) * 1999-11-12 2004-07-01 Pharmasset Ltd Sintesis de 2'-desoxi-l-nucleosidos.
SI1267880T2 (sl) * 2000-02-29 2010-04-30 Bristol Myers Squibb Co Formulacija z nizko dozo entekavirja in uporaba
US20020056123A1 (en) * 2000-03-09 2002-05-09 Gad Liwerant Sharing a streaming video
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
ES2319732T3 (es) * 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA005890B1 (ru) 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
CN101250194B (zh) * 2000-11-29 2011-05-04 三井化学株式会社 L-核酸衍生物及其合成方法
EP1348712B1 (fr) * 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Procédés et intermédiaires dans la synthèse de L-thymidine
WO2003053360A2 (fr) 2001-12-20 2003-07-03 Pharmassett Ltd. Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
WO2003055896A2 (fr) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. 7-deaza l-nucleosides en tant qu'antiviraux
CA2477741A1 (fr) * 2002-02-28 2003-09-04 Biota, Inc. Mimetiques nucleotidiques et leurs promedicaments
ES2254941T3 (es) * 2002-06-27 2006-06-16 Medivir Ab Interaccion sinergica entre abacavir y alovudina.
BR0312278A (pt) * 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2005533817A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
JP4173861B2 (ja) * 2002-09-13 2008-10-29 イデニクス（ケイマン）リミテツド 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法
MXPA05004503A (es) * 2002-10-31 2005-08-16 Metabasis Therapeutics Inc Nuevos profarmacos de monofosfato de citarabina.
EP1576138B1 (fr) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-MÉTHYL-NUCLEOSIDES EN COMBInaISON AVEC l'INTERFÉRON ET MUTATION DE FLAVIVIRIDAE
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
WO2004084453A2 (fr) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides
US7595390B2 (en) 2003-04-28 2009-09-29 Novartis Ag Industrially scalable nucleoside synthesis
WO2004096197A2 (fr) * 2003-05-02 2004-11-11 Universita Degli Studi Di Cagliari 5-aza-7-deazapurine nucleosides pour le traitement de flaviviridae
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
EP1639121A4 (fr) * 2003-06-30 2008-04-16 Idenix Cayman Ltd Synthese de nucleosides beta l-2-desoxy
CN1315863C (zh) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
ES2543840T3 (es) 2006-04-11 2015-08-24 Novartis Ag Inhibidores espirocíclicos del VHC/VIH y sus usos
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
CA2748057C (fr) 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
BRPI0922508A8 (pt) 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
KR101961601B1 (ko) * 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
CN102649788B (zh) * 2011-02-28 2015-03-25 四川大学 β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2852867C (fr) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combinaison de formulation de deux composes antiviraux
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
CN110680806A (zh) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 一种替比夫定颗粒的制备方法
CN108570078A (zh) * 2018-07-18 2018-09-25 荆门医药工业技术研究院 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法
CN114133398B (zh) * 2021-12-31 2022-11-22 中南民族大学 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875971A (en) 1959-01-14 1961-08-30 Hoffmann La Roche A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
EP0355131B1 (fr) 1987-10-28 1996-09-04 Pro-Neuron, Inc. Derives de desoxyribonucleosides d'acyle et leurs utilisations
JP2675864B2 (ja) 1988-07-05 1997-11-12 キヤノン株式会社 被記録材及びこれを用いたインクジェット記録方法
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (fr) 1990-05-29 1991-12-12 Vical, Inc. Synthese de derives de diphosphate et de triphosphate de glycerine
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
WO1992001138A1 (fr) 1990-07-12 1992-01-23 G-Drill Ab Perforatrice hydraulique a roche pour le fond du trou
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
IT1246983B (it) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
RU2116789C1 (ru) 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (fr) 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
JPH07500573A (ja) 1991-07-12 1995-01-19 ネクススター・ファーマシューティカルズ・インコーポレイテッド 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
WO1994020523A1 (fr) * 1993-03-10 1994-09-15 The Wellcome Foundation Limited Ciblage de tumeur au moyen de conjugues oligonucleotidiques l-enantiomeres d'immunoreactifs et de radionucleides chelates
JP3693357B2 (ja) 1993-04-09 2005-09-07 峯郎 実吉 逆転写酵素阻害剤
CA2162574A1 (fr) 1993-05-12 1994-11-24 Karl Y. Hostetler Derives d'acyclovir pour applications topiques
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
CA2171550C (fr) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides avec activite virale anti-hepatite b
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (fr) * 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NOUVEAUX β-L-NUCLEOSIDES ET LEUR UTILISATION
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
CA2322494A1 (fr) 1998-03-11 1999-09-16 Annette M. Gero Nouveaux analogues de nucleosides et leurs utilisations dans le traitement de maladies
MXPA00012842A (es) 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A2 (fr) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
EA005890B1 (ru) * 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ

Also Published As

Publication number Publication date
RU2424016C2 (ru) 2011-07-20
KR100702230B1 (ko) 2007-04-03
KR20010072392A (ko) 2001-07-31
CY1116988T1 (el) 2017-04-05
EP1104436B1 (fr) 2005-12-21
RU2006147216A (ru) 2008-07-10
JP2007269798A (ja) 2007-10-18
CN1606983A (zh) 2005-04-20
PT1431304E (pt) 2015-03-09
LU91348I2 (fr) 2007-09-18
EP1104436A2 (fr) 2001-06-06
CN1320128A (zh) 2001-10-31
DE122007000062I1 (de) 2007-12-20
CY2007017I1 (el) 2009-11-04
KR20060038483A (ko) 2006-05-03
KR20060035817A (ko) 2006-04-26
JP4294870B2 (ja) 2009-07-15
NL300286I1 (nl) 2007-10-01
AU5475799A (en) 2000-03-06
CA2340156C (fr) 2007-10-23
SG132498A1 (en) 2007-06-28
DK1104436T3 (da) 2006-04-03
CN100482236C (zh) 2009-04-29
HK1097776A1 (en) 2007-07-06
CA2340156A1 (fr) 2000-02-24
WO2000009531A2 (fr) 2000-02-24
CY2007017I2 (el) 2009-11-04
FR07C0046I1 (fr) 2007-10-26
DK1431304T3 (en) 2015-03-02
EP2415776A1 (fr) 2012-02-08
CN1257912C (zh) 2006-05-31
HK1111913A1 (en) 2008-08-22
NL300286I2 (nl) 2008-01-02
KR100634342B1 (ko) 2006-10-16
PT2415776T (pt) 2016-07-07
US20080064655A1 (en) 2008-03-13
ES2579903T3 (es) 2016-08-17
KR20050062664A (ko) 2005-06-23
US20030225028A1 (en) 2003-12-04
US7304043B2 (en) 2007-12-04
ATE313550T1 (de) 2006-01-15
HK1034083A1 (en) 2001-10-12
CN1478483A (zh) 2004-03-03
BRPI9912896B1 (pt) 2016-08-09
LU91348I9 (fr) 2018-12-31
ES2255295T3 (es) 2006-06-16
EP2415776B1 (fr) 2016-05-25
DK2415776T3 (en) 2016-07-04
WO2000009531A3 (fr) 2000-06-15
BR9912896A (pt) 2002-02-13
DE69929060T2 (de) 2006-08-31
DE69929060D1 (de) 2006-01-26
ES2531928T3 (es) 2015-03-20
US20060084624A1 (en) 2006-04-20
US6569837B1 (en) 2003-05-27
KR100568035B1 (ko) 2006-04-07
MXPA01001507A (es) 2003-09-10
CN100387237C (zh) 2008-05-14
BRPI9912896B8 (pt) 2021-05-25
JP2002522552A (ja) 2002-07-23
US6395716B1 (en) 2002-05-28
KR100691737B1 (ko) 2007-03-12

Similar Documents

Publication Publication Date Title
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
DE69731674D1 (de) Silencieux d'aspiration pour compresseur
MA25823A1 (fr) Compositions pour le traitement de l'eau.
DZ2396A1 (fr) Traitement de l'eau
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
FR2771297B1 (fr) Sonde bicanaliculaire pour le traitement du larmoiement de l'oeil
FR2722681B1 (fr) Calecon pour homme
FR2758465B1 (fr) Composition pour le traitement de l'amiante
FR2710267B3 (fr) Composition pour le traitement de l'impuissance masculine.
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2747398B1 (fr) Procede de traitement de surface d'une piece metallique
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
FR2775199B1 (fr) Materiau composite pour le traitement d'effluents photographiques
NO991158L (no) FremgangsmÕte for behandling av amyotrofisk lateralsklerose
FR2751637B1 (fr) Cellule d'electrocoagulation pour le traitement d'effluents
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c
FR2759290B1 (fr) Minalcipran pour le traitement de l'incontinence urinaire
MA23737A1 (fr) Trousse pour cycle de traitement de l'osteoporose